Lege Artis Medicinae

[Personal genom - brave new world?]

KÓSA János Pál

JUNE 15, 2012

Lege Artis Medicinae - 2012;22(05)

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Quo vadis? Whose life is it anyway? EBM based health politics and health based politics]

KAPÓCS Gábor

Lege Artis Medicinae

[The Personality of Genious Artists: Gustav Klimt]

CZEIZEL Endre

Lege Artis Medicinae

[Borderline and Stigmatisation An Interview with Éva Ratkóczi MD ]

NAGY Zsuzsanna

Lege Artis Medicinae

[Insulin dose titration in type 1 diabetes mellitus: A blessing or a curse?]

TAKÁCS Róbert

[INTRODUCTION - Knowing the pharmacokinetic properties of different insulins, useful treatment algorithms can be set up for the majority of our insulin-treated patients. When planning either a human or an analogue basal-bolus regimen, the first task is to determine the daily insulin requirement, followed by determination of the optimal rate of basal and bolus insulins. CASE REPORT - In a 33-year old, moderately obese man with type 1 diabetes who received 180 U daily insulin doses, accumulated hypoglycaemic episodes with neuroglycopenic symptoms occured. After cessation of the original insulin therapy and starting an analogue basal-bolus treatment regimen, both the carbohydrate metabolism and the overall quality of life of the patient have significantly improved. Optimal metabolic control was achieved by a basal insulin ratio above 50%. CONCLUSION - Using elements of the analogue basal-bolus regimen - one of the state-of-the-art forms of insulin treatment - at the appropriate dose and dose ratio, it is possible to comply with the therapeutic requirements of our age. However, if this weapon is used inappropriately, it might actually harm patients.]

Lege Artis Medicinae

[The role of vitamin D in gastrointestinal diseases]

ZÖLD Éva, BODOLAY Edit, ZEHER Zargit, BARTA Zsolt

[The amount of the fat-soluble vitamin D can be reduced by a number of chronic diseases or even obesity. On the other hand, vitamin D itself can also influence the development or course of these disorders. Some gastrointestinal diseases are known to cause vitamin D deficiency, but some observations and studies have also proved that certain gastrointestinal diseases occur more frequently in case of vitamin D deficiency. Moreover, in case of some intestinal tumours even “vitamin D sensitivity” can occur. Our aim is to introduce the relationship between vitamin D and gastrointestinal diseases, and to highlight the importance of vitamin D replacement in gastrointestinal diseases accompanied by vitamin D deficiency or vitamin D sensitivity.]

All articles in the issue

Related contents

Clinical Neuroscience

[Clinical neurophysiological methods in diagnosis and treatment of cerebrovascular diseases]

NAGY Ildikó, FABÓ Dániel

[Neurophysiological methods are gaining ground in the diagnosis and therapy of cerebrovascular disease. While the role of the EEG (electroencephalography) in the diagnosis of post-stroke epilepsy is constant, quantitative EEG para-meters, as new indicators of early efficiency after thrombolysis or in prognosis of patient’s condition have proved their effectiveness in several clinical studies. In intensive care units, continuous EEG monitoring of critically ill patients became part of neurointenzive care protocols. SSEP (somatosesnsory evoked potencial) and EEG performed during carotid endarterectomy, are early indicative intraoperativ neuromonitoring methods of poor outcome. Neurorehabilitation is a newly discovered area of neurophysiology. Clinical studies have demonstrated the effectiveness of repetitive transcranial magnetic stimulation (rTMS) in the rehabilitation of stroke patients. Brain computer interface mark the onset of modern rehabi-litation, where the function deficit is replaced by robotic tehnology. ]

Clinical Neuroscience

[Earlier and more efficiently: the role of deep brain stimulation for parkinson’s disease preserving the working capabilities]

GABRIELLA BALÁS, ISTVÁN KOMOLY, SÁMUEL DÓCZI, TAMÁS JANSZKY, JÓZSEF ASCHERMANN, ZSUZSANNA NAGY, FERENC BOSNYÁK, EDIT KOVÁCS

[Background – The recently published “EarlyStim” study demonstrated that deep brain stimulation (DBS) for the treatment of Parkinson’s disease (PD) with early fluctuations is superior to the optimal pharmacological treatment in improving the quality of life and motor symptoms, and preserving sociocultural position. Our retrospective investigation aimed to evaluate if DBS therapy was able to preserve the working capabilities of our patients. Methods – We reviewed the data of 39 young (<60 years-old) PD patients who underwent subthalamic DBS implantation at University of Pécs and had at least two years follow-up. Patients were categorized into two groups based on their working capabilities: Patients with active job (“Job+” group, n=15) and retired patients (without active job, “Job-” group, n=24). Severity of motor symptoms (UPDRS part 3), quality of life (EQ-5D) and presence of active job were evaluated one and two years after the operation. Results – As far as the severity of motor symptoms were concerned, similar (approximately 50%) improvement was achieved in both groups. However, the postoperative quality of life was significantly better in the Job+ group. Majority (12/15, 80%) of Job+ group members were able to preserve their job two years after the operation. However, only a minimal portion (1/24, 4.2%) of the Job- group members was able to return to the world of active employees (p<0.01, McNemar test). Conclusion – Although our retrospective study has several limitations, our results fit well with the conclusions of “EarlyStim” study. Both of them suggest that with optimal timing of DBS implantation we may preserve the working capabilities of our patients.]

Hypertension and nephrology

[Functional and morphologic changes in patients with new-onset dyslipidemia after transplantation]

BORDA Bernadett, LENGYEL Csaba, VÁRKONYI Tamás, SZABÓ Viktor, SZEDERKÉNYI Edit, LÁZÁR György

[The principal risk factors for cardiovascular mortality after transplantation are hyperglycemia, hypertriglyceridemia, immunosuppressive therapy, obesity, and smoking. Among 115 patients, we assessed the risk factors for new-onset dyslipidemia, and their effects on the function and histopathology changes in the allografts one year after transplantation. Evaluating the risk factors and the initial recipient data, we observed a significant difference in age when comparing normal versus new-onset dyslipidemia patients (p=0.002). The difference in body mass index was significant one year after kidney transplantation when comparing normal with new-onset dyslipidemia patients (p=0.02). The trigliceride levels were significantly higher among those on cyclosporine- A than those on tacrolimus (3.02±1.51 mmol/l vs 2.15±1.57 mmol/l, p=0.004). The difference also proved to be significant for the total cholesterol level: 5.43±1.23 mmol/l versus 4.42±1.31 mmol/l respectively (p=0.001). In regard to allograft function there was no significant difference one year after transplantation between the normal and new-onset dyslipidemia patients. When assessing morphologic changes in the kidney, we observed significantly more frequent interstitial fibrosis/tubular atrophy among new-onset dyslipidemia than normal function patients. Disruption of lipid homeostasis is known to severely damage the allograft. Without timely recognition and treatment, these conditions may not only lead to irreversible damage in the allograft, but also increase cardiovascular risk.]

Lege Artis Medicinae

[Drug treatment possibilities in chronic liver diseases]

HAGYMÁSI Krisztina, LENGYEL Gabriella, FEHÉR János

[Alcoholic and drug induced liver diseases, nonalcoholic steatohepatitis, hepatitis C and B chronic hepatitis, autoimmune diseases (primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis) and metabolic disorders (hemochromatosis, Wilson's disease) are the main chronic liver diseases. Authors summarize, based on the latest literature data, the medications of chronic liver diseases, emphasizing the treatment of the everyday practice. Natural and synthetic antioxidants are approved for the treatment of chronic alcoholic liver diseases besides abstinence, with diet of adequate quality and quantity. Nucleoside analogues (lamivudin) are recommended for the first-line therapy of the treatment of chronic hepatitis B. Interferon is presently considered the optimal treatment for only certain patients. Interferon and ribavirin combined therapy is well-established in the treatment of chronic hepatitis C. Ursodeoxycholic acid is the beneficial treatment option for primary biliary cirrhosis and primary sclerosing cholangitis. Prednisolon and azathioprine constitute the basic therapy of autoimmune hepatitis. Presumably, in the future, new strategies based on immunosuppressive combinations will play a crucial role. The chelating deferoxamine has less important part in the treatment of hemochromatosis. D-penicillamine still plays principle role in the medication of Wilson's disease.]

Lege Artis Medicinae

[Effect of beta blockers in hypertension, ischaemic heart disease, heart failure and metabolic syndrome]

BENCZÚR Béla

[Beta-blockers are among the most widely used drugs for the treatment of cardiovascular diseases. In the mid-90’s, these drugs were recommended as first-line therapies of hypertension. With the introduction of new drugs, the list of first-choice drugs has been extended. The results of recently published major hypertension trials, which compared conventional agents (beta blockers and/or diuretics) with newer agents (angiotensin converting enzyme inhibitors, Caantagonists, angiotensin receptor blockers), raised concerns regarding the role of beta blockers in cardiovascular primary prevention. Subsequently, a metaanalysis of 13 trials has shown that compared with other drug types, beta-blocker therapy is less beneficial in patients with hypertension who do not have heart disease. Nevertheless, in cardiovascular indications other than hypertension (acute myocardial infarction, heart failure and arrhythmias), betablockers retain their dominant position.]